BioWorld MedTech

Sep. 5, 2018

View Archived Issues

Nexstim scraps FDA approval plans for TMS system in rehabilitation following stroke

LONDON – Nexstim plc has dropped plans to apply for FDA approval of its transcranial magnetic stimulation (TMS) system in rehabilitation following stroke, after a second U.S. phase III trial failed to reach statistical significance. Read More

Attune Medical scoops up more than $15M in oversubscribed series C

Read More

Belgian startup Miracor bumps series D up to €30M to back novel treatment after AMI

Read More

Study says CJR program cut spending without affecting outcomes

Read More

Astraea's bifunctional drug fights pain and addiction

Read More

Financings

Read More

Daily M&A

Read More

Appointments and advancements

Read More

Product briefs

Read More

Other news to note

Read More

BioWorld MedTech's Oncology Extra

Read More